The 3 most recent market catalysts affecting $VRXA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 24, 2026
Corporate Catalyst
Bullish
Impact 65
VERAXA Biotech Announces Initial Results From Strategic Research Collaboration To Develop Next-Generation Antibody Oligonucleotide Conjugates For Autoimmune And Chronic Immune Diseases; In Early In Vitro Studies, An AOC Candidate Demonstrated Greater Potency
VERAXA Biotech and Secarna Pharmaceuticals reported initial positive in vitro results from their strategic research collaboration. This filing is significant because it validates V…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 65
VERAXA Biotech Advances Bispecific ADC VXA‑222 With OmniAb Milestone, Moving Alliance Into Next Phase Of Cancer Therapy Discovery
VERAXA Biotech has announced a significant step forward in its bispecific ADC program, VXA-222, by achieving a technical milestone with its partner OmniAb. This indicates successfu…
Jul 20, 2026
Corporate Catalyst
Bullish
Impact 55
VERAXA Gets German Regulatory Feedback On Cancer Therapy Plan
VERAXA Biotech announced that it received supportive Scientific Advice from the Paul-Ehrlich-Institute (PEI), the German regulatory authority, concerning its BiTAC-TCE cancer thera…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.